Ablative Solutions, Inc.

Ablative Solutions, Inc. is a clinical-stage medical device company developing innovative catheter-based treatments for hypertension by targeting the sympathetic nervous system. The company's primary product, the Peregrine System Kit, uses transcatheter perivascular alcohol infusion to deliver dehydrated alcohol to the renal arteries, disrupting overactive renal nerves to reduce blood pressure. Founded in 2011 and based in Wakefield, Massachusetts, Ablative Solutions has raised $149.8 million in funding and is advancing the Peregrine System through clinical trials, including the TARGET BP I Pivotal Trial, toward FDA approval. The company also explores expanded applications of alcohol renal denervation beyond hypertension management.